{"entity":{"id":"nct07024706","kind":"trial","name":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","aka":["MAVRiC"],"tldr":"A phase 2 trial of Acalabrutinib and Venetoclax in chronic lymphocytic leukaemia, run by AstraZeneca, now recruiting.","summary":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab is a phase 2 interventional study registered as NCT07024706 by AstraZeneca, with 80 participants planned, started 2026-06-04 and due to reach its primary completion in 2029-05-01. Interventions recorded: Acalabrutinib and Venetoclax.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07024706","url":"https://clinicaltrials.gov/study/NCT07024706"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":["bcl2-inhibitors","kinase-inhibitors"],"targets":[],"drugs":["acalabrutinib","venetoclax"],"companies":["astrazeneca","abbvie","flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07024706","phase":"2","setting":"The MAVRiC Study: A Phase II Study of Disease Risk Mutation Guided Finite Duration Acalabrutinib Plus Venetoclax for Relapse in CLL/SLL After First-line Finite Covalent BTKi Plus BCL2i Combination, With or Without Obinutuzumab","sponsor":"AstraZeneca","participation":[{"nct":"NCT07024706","source":"https://clinicaltrials.gov/study/NCT07024706","fetchedAt":"2026-10-07T16:55:22.250Z","studySha256":"57795c1057dc9b440830ddc2ad21357038242a3be17c831c31763ad5798e4ef1","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-06","leadSponsor":"AstraZeneca","collaboratorCount":2,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":80,"enrolmentType":"ESTIMATED","siteCount":36,"recruitingSiteCount":15,"countries":["Austria","Brazil","Czechia","Ireland","Italy","Poland","Spain","United States"]}],"started":"2026-06-04","startedType":"actual","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07024706/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"technology":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}]}}